Garry Pairaudeau
Chief Tech/Sci/R&D Officer chez Exscientia AI Ltd.
Profil
Garry Pairaudeau is currently the Chief Technology Officer at Exscientia AI Ltd.
He previously worked at AstraZeneca PLC as the Head-Hit Discovery from 2017 to 2020.
He also worked as the Chief Technology Officer at Exscientia Plc from 2020 to 2023.
Dr. Pairaudeau received his undergraduate and doctorate degrees from The University of Southampton.
Postes actifs de Garry Pairaudeau
| Sociétés | Poste | Début |
|---|---|---|
Exscientia AI Ltd.
 Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | Chief Tech/Sci/R&D Officer | 01/11/2020 |
Anciens postes connus de Garry Pairaudeau
| Sociétés | Poste | Fin |
|---|---|---|
| EXSCIENTIA PLC | Chief Tech/Sci/R&D Officer | 30/06/2023 |
| ASTRAZENECA PLC | Corporate Officer/Principal | 01/11/2020 |
Formation de Garry Pairaudeau
| The University of Southampton | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| EXSCIENTIA PLC | Health Technology |
| Entreprise privées | 1 |
|---|---|
Exscientia AI Ltd.
Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | Health Technology |
